Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-
Clinical Trials
Related News

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

First Posted Date
2018-08-09
Last Posted Date
2024-02-13
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
13
Registration Number
NCT03623373
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD

First Posted Date
2018-08-06
Last Posted Date
2024-04-12
Lead Sponsor
Polish Lymphoma Research Group
Target Recruit Count
115
Registration Number
NCT03615664
Locations
🇵🇱

Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland

🇵🇱

Szpitale Pomorskie Sp. z o.o., Gdynia, Poland

🇵🇱

Oddział Chorób Wewnętrznych i Chemioterapii Onkologicznej, Samodzielny Publiczny Szpital Kliniczny im. A.Mielęckiego, Katowice, Poland

and more 10 locations

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Phase 2
Active, not recruiting
Conditions
Chronic Lymphocytic Leukemia
Interventions
Drug: Bendamustine
Drug: Venetoclax
Drug: Rituximab
First Posted Date
2018-08-01
Last Posted Date
2024-04-02
Lead Sponsor
Nicole Lamanna
Target Recruit Count
42
Registration Number
NCT03609593
Locations
🇺🇸

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

First Posted Date
2018-07-26
Last Posted Date
2024-10-26
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
59
Registration Number
NCT03602157
Locations
🇺🇸

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

First Posted Date
2018-07-19
Last Posted Date
2024-10-09
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
86
Registration Number
NCT03593018
Locations
🇧🇪

CHU UCL Namur - Site Godinne, Yvoir, Belgium

🇦🇹

Medical University of Vienna, Vienna, Austria

🇧🇪

A. Z. Sint-Jan Brugge-Oostende AV, Bruges, Belgium

and more 24 locations

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

First Posted Date
2018-05-14
Last Posted Date
2024-11-11
Lead Sponsor
Noah Merin
Target Recruit Count
20
Registration Number
NCT03524235
Locations
🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

First Posted Date
2018-04-10
Last Posted Date
2023-03-31
Lead Sponsor
Prof. Dr. Wolfgang Hiddemann
Target Recruit Count
46
Registration Number
NCT03492775
Locations
🇩🇪

Klinikum der Universität München, München, Bavaria, Germany

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

First Posted Date
2018-02-06
Last Posted Date
2022-06-29
Lead Sponsor
Incyte Corporation
Target Recruit Count
50
Registration Number
NCT03424122
Locations
🇺🇸

Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States

🇺🇸

University of Arizona Cancer Center - Out Pt., Tucson, Arizona, United States

🇺🇸

Texas Oncology, Austin, Texas, United States

and more 18 locations

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

First Posted Date
2018-01-23
Last Posted Date
2024-08-06
Lead Sponsor
AbbVie
Target Recruit Count
120
Registration Number
NCT03406156
Locations
🇺🇸

Oncology Hematology Care, Inc. /ID# 202397, Cincinnati, Ohio, United States

🇺🇸

Tennessee Oncology-Nashville Centennial /ID# 201098, Nashville, Tennessee, United States

🇺🇸

Arizona Oncology Associates, PC-HOPE /ID# 202335, Tempe, Arizona, United States

and more 12 locations

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

First Posted Date
2017-11-24
Last Posted Date
2024-12-04
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
28
Registration Number
NCT03352765
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy